<DOC>
	<DOCNO>NCT01027468</DOCNO>
	<brief_summary>200 eye subtype neovascular age-related macular degeneration include study 3 year initial intravitreal bevacizumab , best-corrected visual acuity ( BCVA ) measure use Snellen chart 6m . Central retinal thickness ( CRT ) measure use Stratus OCT Cirrus SD-OCT ( Zeiss ) . Data treatment-naive eye ( group 1 ) compare data eye undergone prior treatment photodynamic therapy verteporfin intravitreal triamcinolone acetonide ( group 2 ) .</brief_summary>
	<brief_title>Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description>In interventional clinical study , 181 eye 160 consecutive patient active neovascular relate macular degeneration meeting recommend criterion inclusion protocol criterion anti-vascular endothelial growth factor therapy undergoing intravitreal bevacizumab monotherapy evaluate . Data treatment-naive eye ( Group 1 , n = 114 ) analyze separately eyes undergone previous photodynamic therapy plus intravitreal triamcinolone ( Group 2 , n = 67 ) . Re-treatment criterion base clinical outcome follow official European label regimen . After 1 year continuous service academic referral center , follow-up performed private practice collaboration referral center . Main outcome parameter best-corrected visual acuity central retinal thickness .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>subtype neovascular agerelated macular degeneration age 50 year old initial treatment intravitreal bevacizumab August 2005 June 2006 previous vitrectomy presence cystoid macular edema without choroidal neovascularization Uncontrolled sytemic disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>bevacizumab , choroidal neovascularization</keyword>
</DOC>